Delivery Order SPE2DR25D3505-SPE2DR26F97A0

The Defense Logistics Agency awarded a delivery order to AmerSourceBergen Drug Corp (subsidiary of Cencora, Inc.) on January 14, 2026, for the supply of Vemlidy 25 mg tablets in quantities of 30 tablets, with a ceiling value of $1,802.78 and an ultimate completion date of January 15, 2026. The contract utilizes a firm fixed-price structure with no small business set-aside designation. Performance will take place at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerSourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026, which serves as the comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to military healthcare programs worldwide.

Vemlidy is an antiviral medication used in the treatment of chronic hepatitis B, reflecting DLA's ongoing procurement of specialty pharmaceuticals to support military and veteran healthcare systems. AmerSourceBergen Drug Corp's role as a critical pharmaceutical distributor within the federal supply chain is evidenced by its competitively awarded contracts spanning multiple therapeutic domains, including specialty medications, vaccines, and medical devices. The parent organization, Cencora, Inc., also maintains a separate and substantially larger IDC with the Defense Logistics Agency valued at up to $999,999,999.00 through December 2031, underscoring the company's significance as a primary vendor for federal pharmaceutical and medical commodity procurement.